BeOne Medicines AG (BEIGF)

Market Cap	34.22B
Revenue (ttm)	4.56B
Net Income (ttm)	-177.64M
Shares Out	n/a
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	68.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	459
Open	22.51
Previous Close	15.95
Day's Range	22.51 - 22.51
52-Week Range	13.68 - 22.51
Beta	0.31
RSI	59.98
Earnings Date	Nov 6, 2025

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: OTCMKTS
• Ticker Symbol: BEIGF

Financial Performance

In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.